Summary:
- Medtronic, a leading medical technology company, has invested in Anteris (ASX: AVR), a medical device company, to fund the clinical trial for Anteris's DurAVR transcatheter aortic valve replacement (TAVR) system.
- The investment will also support the expansion of Anteris's TAVR platform, which is designed to provide a longer-lasting and more durable solution for patients with aortic valve disease.
- This collaboration between Medtronic and Anteris aims to advance the development of innovative TAVR technologies, potentially improving the quality of life for patients with aortic valve issues.